A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis - Novotna, A.; Mares, J.; Ratcliffe, S.; Novakova, I.; Vachova, M.; Zapletalova, O.; Gasperini, C.; Pozzilli, C.; Cefaro, L.; Comi, G.; Rossi, P.; Ambler, Z.; et al. (European journal of neurology, 2011)
Keywords: Adult; Aged; Cannabidiol; cannabinoids; Clinical trials; delta-9-tetrahydrocannabinol; Double-Blind Method; Dronabinol; Drug Combinations; endocannabinoid system; Female; Humans; Male; Middle Aged; Multiple sclerosis; Multiple Sclerosis - complications; Multiple Sclerosis - drug therapy; Muscle Spasticity - drug therapy; Muscle Spasticity - etiology; nabiximols; Plant Extracts - therapeutic use; Sativex; Sleep; spasticity